Incyte, Medarex Announce Deal to Develop Antibody Therapeutics | GenomeWeb

NEW YORK, Oct. 18 – Incyte Genomics and Medarex said Thursday they would work together to develop and commercialize human antibody therapeutics.

Under the terms of the deal, Medarex and Incyte will share the preclinical and clinical development costs associated with developing antibody products. The two companies said they would also jointly sell and distribute products resulting from the collaboration.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.